RABL6A is an essential driver of MPNSTs that negatively regulates the RB1 pathway and sensitizes tumor cells to CDK4/6 inhibitors.
CONCLUSIONS: RABL6A is a new driver of MPNST pathogenesis that acts in part through p27-RB1 inactivation. Our results suggest RB1 targeted therapy with multiple pathway drugs may effectively treat MPNSTs.
PMID: 32086342 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Kohlmeyer JL, Kaemmer CA, Pulliam C, Maharjan CK, Moreno Samayoa A, Major HJ, Cornick KE, Knepper-Adrian V, Khanna R, Sieren JC, Leidinger M, Meyerholz DK, Zamba KD, Weimer J, Dodd RD, Darbro B, Tanas MR, Quelle DE Tags: Clin Cancer Res Source Type: research
More News: Cancer | Cancer & Oncology | Disability | Eye Cancers | Molecular Biology | Retinoblastoma | Sarcomas